WallStSmart

Procter & Gamble Company (PG)vs22nd Century Group Inc (XXII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Procter & Gamble Company generates 1230103% more annual revenue ($86.72B vs $7.05M). PG leads profitability with a 19.2% profit margin vs -71.7%. PG earns a higher WallStSmart Score of 61/100 (C+).

PG

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 3.01

XXII

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PGSignificantly Overvalued (-37.3%)

Margin of Safety

-37.3%

Fair Value

$107.17

Current Price

$147.09

$39.92 premium

UndervaluedFair: $107.17Overvalued
XXIIUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$19.09

Current Price

$1.56

$17.53 discount

UndervaluedFair: $19.09Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PG5 strengths · Avg: 9.2/10
Market CapQuality
$342.51B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
31.1%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
3.0110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
23.1%8/10

Strong operational efficiency at 23.1%

Free Cash FlowQuality
$3.03B8/10

Generating 3.0B in free cash flow

XXII1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

PG1 concerns · Avg: 2.0/10
PEG RatioValuation
4.082/10

Expensive relative to growth rate

XXII4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.20M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-116.6%2/10

ROE of -116.6% — below average capital efficiency

Revenue GrowthGrowth
-43.1%2/10

Revenue declined 43.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : PG

The strongest argument for PG centers on Market Cap, Return on Equity, Altman Z-Score. Profitability is solid with margins at 19.2% and operating margin at 23.1%.

Bull Case : XXII

The strongest argument for XXII centers on Price/Book.

Bear Case : PG

The primary concerns for PG are PEG Ratio.

Bear Case : XXII

The primary concerns for XXII are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

PG profiles as a mature stock while XXII is a turnaround play — different risk/reward profiles.

XXII carries more volatility with a beta of 1.12 — expect wider price swings.

PG is growing revenue faster at 7.4% — sustainability is the question.

PG generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

PG scores higher overall (61/100 vs 31/100), backed by strong 19.2% margins. XXII offers better value entry with a 70.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Procter & Gamble Company

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

The Procter & Gamble Company (P&G) is an American multinational consumer goods corporation headquartered in Cincinnati, Ohio, founded in 1837 by William Procter and James Gamble. It specializes in a wide range of personal health, consumer health, personal care, and hygiene products; these products are organized into several segments including Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine, & Family Care. Before the sale of Pringles to Kellogg's, its product portfolio also included food, snacks, and beverages.

Visit Website →

22nd Century Group Inc

CONSUMER DEFENSIVE · TOBACCO · USA

22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural company dedicated to tobacco harm reduction through advanced genetic engineering techniques. By focusing on the development of low-nicotine tobacco products, the firm aims to mitigate nicotine addiction while enhancing public health outcomes. As it strategically diversifies into the burgeoning hemp and cannabis markets, 22nd Century positions itself to capitalize on the expanding legal cannabis landscape. With a robust commitment to scientific research and adherence to regulatory frameworks, the company represents a compelling investment opportunity for institutional investors looking to engage in transformative sectors.

Want to dig deeper into these stocks?